دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift
Kevin D. Deane V. Michael Holers
doi : 10.1002/art.41417
Volume73, Issue2,Pages 181-193
Rheumatoid arthritis (RA) is currently diagnosed and treated when an individual presents with signs and symptoms of inflammatory arthritis (IA) as well as other features, such as autoantibodies and/or imaging findings, that provide sufficient confidence that the individual has RA?like IA (e.g., meeting established classification criteria) that warrants therapeutic intervention. However, it is now known that there is a stage of seropositive RA during which circulating biomarkers and other factors (e.g., joint symptoms) can be used to predict if and when an individual who does not currently have IA may develop future clinically apparent IA and classifiable RA. Indeed, the discovery of the “pre?RA” stage of seropositive disease has led to the development of several clinical trials in which individuals are studied to identify ways to delay or prevent the onset of clinically apparent IA/RA. This review focuses on several issues pertinent to understanding the prevention of RA. These include discussion of the pathogenesis of pre?RA development, prediction of the likelihood and timing of future classifiable RA, and a review of completed and ongoing clinical trials in RA prevention. Furthermore, this review discusses challenges and opportunities to be addressed to effect a paradigm shift in RA, where in the near future, proactive risk assessment focused on prevention of RA will become a public health strategy in much the same manner as cardiovascular disease is managed today.
Urinary Biomarkers in Lupus Nephritis: Are We There Yet?
Chi Chiu Mok Chandra Mohan
doi : 10.1002/art.41508
Volume73, Issue2,Pages 194-196
no abstract
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID?19 Pandemic: Version 3
Ted R. Mikuls Sindhu R. Johnson Liana Fraenkel Reuben J. Arasaratnam Lindsey R. Baden Bonnie L. Bermas Winn Chatham Stanley Cohen Karen Costenbader Ellen M. Gravallese Andre C. Kalil Michael E. Weinblatt Kevin Winthrop Amy S. Mudano Amy Turner Kenneth G. Saag
doi : 10.1002/art.41596
Volume73, Issue2,Pages e1-e12
To provide guidance to rheumatology providers on the management of adult rheumatic disease in the context of the coronavirus disease 2019 (COVID?19) pandemic.
Health Assessment Questionnaire at One Year Predicts All?Cause Mortality in Patients With Early Rheumatoid Arthritis
Safoora Fatima O. Schieir M. F. Valois S. J. Bartlett L. Bessette G. Boire G. Hazlewood C. Hitchon E. C. Keystone D. Tin C. Thorne V. P. Bykerk J. E. Pope the CATCH Investigators
doi : 10.1002/art.41513
Volume73, Issue2,Pages 197-202
Higher self?reported disability (high Health Assessment Questionnaire [HAQ] score) has been associated with hospitalizations and mortality in established rheumatoid arthritis (RA), but associations in early RA are unknown.
Obesity?Related Traits and the Development of Rheumatoid Arthritis: Evidence From Genetic Data
Bowen Tang Huwenbo Shi Lars Alfredsson Lars Klareskog Leonid Padyukov Xia Jiang
doi : 10.1002/art.41517
Volume73, Issue2,Pages 203-211
To investigate the association between obesity?related traits and risk of rheumatoid arthritis (RA).
Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis
Weiyang Tao Arno N. Concepcion Marieke Vianen Anne C. A. Marijnissen Floris P. G. J. Lafeber Timothy R. D. J. Radstake Aridaman Pandit
doi : 10.1002/art.41516
Volume73, Issue2,Pages 212-222
To predict response to anti–tumor necrosis factor (anti?TNF) prior to treatment in patients with rheumatoid arthritis (RA), and to comprehensively understand the mechanism of how different RA patients respond differently to anti?TNF treatment.
Patients’ Preoperative Expectations of Total Knee Arthroplasty and Satisfaction With Outcomes at One Year: A Prospective Cohort Study
Gillian A. Hawker Barbara L. Conner?Spady Eric Bohm Michael J. Dunbar C. Allyson Jones Bheeshma Ravi Tom Noseworthy Donald Dick James Powell Paulose Paul Deborah A. Marshall the BEST?Knee Study Team
doi : 10.1002/art.41510
Volume73, Issue2,Pages 223-231
To assess the relationship between patients’ expectations for total knee arthroplasty (TKA) and satisfaction with surgical outcome.
Repair of Bone Erosion With Effective Urate?Lowering Therapy in a Patient With Tophaceous Gout
Shota Sakaguchi
doi : 10.1002/art.41509
Volume73, Issue2,Pages 231-231
An Autoimmunogenic and Proinflammatory Profile Defined by the Gut Microbiota of Patients With Untreated Systemic Lupus Erythematosus
Bei?di Chen Xin?miao Jia Jia?yue Xu Li?dan Zhao Jun?yi Ji Bing?xuan Wu Yue Ma Hao Li Xiao?xia Zuo Wen?you Pan Xiao?han Wang Shuang Ye George C. Tsokos Jun Wang Xuan Zhang
doi : 10.1002/art.41511
Volume73, Issue2,Pages 232-243
Changes in gut microbiota have been linked to systemic lupus erythematosus (SLE), but knowledge is limited. Our study aimed to provide an in?depth understanding of the contribution of gut microbiota to the immunopathogenesis of SLE.
Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus Nephritis
Juan M. Mejia?Vilet John P. Shapiro Xiaolan L. Zhang Cristino Cruz Grant Zimmerman R. Angélica Méndez?Pérez Mayra L. Cano?Verduzco Samir V. Parikh Haikady N. Nagaraja Luis E. Morales?Buenrostro Brad H. Rovin
doi : 10.1002/art.41507
Volume73, Issue2,Pages 244-254
To evaluate the role of urinary epidermal growth factor (EGF) as a biomarker of chronic kidney damage in lupus nephritis (LN).
Effects of BAFF Neutralization on Atherosclerosis Associated With Systemic Lupus Erythematosus
Fanny Saidoune Guillaume Even Yasmine Lamri Julie Chezel Anh?Thu Gaston Brigitte Escoubet Thomas Papo Nicolas Charles Antonino Nicoletti Karim Sacre
doi : 10.1002/art.41485
Volume73, Issue2,Pages 255-264
Cardiovascular disease (CVD) is the leading cause of death in systemic lupus erythematosus (SLE). B cells play a key role in the pathogenesis of lupus, and anti?BAFF therapy has been approved for use in SLE. Since mature B cells also promote atherosclerosis, we undertook this study to evaluate, in a mouse model and in SLE patients, whether BAFF neutralization has an atheroprotective effect in SLE.
Association of Urinary Matrix Metalloproteinase 7 Levels With Incident Renal Flare in Lupus Nephritis
Guobao Wang Liling Wu Huanjuan Su Xiaodan Feng Meng Shi Lingwei Jin Manqiu Yang Zhanmei Zhou Cailing Su Bihui Yang Yajing Li Wei Cao
doi : 10.1002/art.41506
Volume73, Issue2,Pages 265-275
Flares of lupus nephritis (LN) are frequent and associated with impaired renal prognosis. One major management obstacle in LN flare is the lack of effective methods to identify at?risk patients earlier in their disease course. This study was undertaken to test the utility of measurement of urinary matrix metalloproteinase 7 (MMP?7) for the dynamic surveillance of renal disease activity and prediction of renal flares in LN.
Deficiency of Adenosine Deaminase 2 in Adults and Children: Experience From India
Aman Sharma GSRSNK Naidu Vikas Sharma Saket Jha Aaadhar Dhooria Varun Dhir Prateek Bhatia Vishal Sharma Sagar Bhattad K. G. Chengappa Vikas Gupta Durga Prasanna Misra Pallavi Pimpale Chavan Sourabh Malaviya Rajkiran Dudam Banwari Sharma Sathish Kumar Rajesh Bhojwani Pankaj Gupta Vikas Agarwal Kusum Sharma Manphool Singhal Manish Rathi Ritambhra Nada Ranjana W. Minz Ved Chaturvedi Amita Aggarwal Rohini Handa Alice Grossi Marco Gattorno Zhengping Huang Jun Wang Ramesh Jois V. S. Negi Raju Khubchandani Sanjay Jain Juan I. Arostegui Eugene P. Chambers Michael S. Hershfield Ivona Aksentijevich Qing Zhou Pui Y. Lee
doi : 10.1002/art.41500
Volume73, Issue2,Pages 276-285
Deficiency of adenosine deaminase 2 (DADA2) is a potentially fatal monogenic syndrome characterized by variable manifestations of systemic vasculitis, bone marrow failure, and immunodeficiency. Most cases are diagnosed by pediatric care providers, given the typical early age of disease onset. This study was undertaken to describe the clinical phenotypes and treatment response both in adults and in children with DADA2 in India.
Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A Case–Control Study
Laure Delaval Maxime Samson Flora Schein Christian Agard Ludovic Tréfond Alban Deroux Henry Dupuy Cyril Garrouste Pascal Godmer Cédric Landron François Maurier Guillaume le Guenno Virginie Rieu Julien Desblache Cécile?Audrey Durel Laurence Jousselin?Mahr Hassan Kassem Grégory Pugnet Vivane Queyrel Laure Swiader Daniel Blockmans Karim Sacré Estibaliz Lazaro Luc Mouthon Olivier Aumaître Pascal Cathébras Loic Guillevin Benjamin Terrier the French Vasculitis Study Group and French Study Group for Giant Cell Arteritis
doi : 10.1002/art.41527
Volume73, Issue2,Pages 286-294
Temporal arteritis (TA) is a typical manifestation of giant cell arteritis (GCA). Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides (AAVs) are rarely revealed by TA manifestations, leading to a risk of misdiagnosis of GCA and inappropriate treatments. This study was undertaken to describe the clinical, biologic, and histologic presentations and outcomes in cases of TA revealing AAV (TA?AAV) compared to controls with classic GCA.
Spondylitis as a Rare Manifestation of Granulomatosis With Polyangiitis
Matthias H. Busch Joop P. Aendekerk Astrid M. L. Oude Lashof Pieter van Paassen
doi : 10.1002/art.41565
Volume73, Issue2,Pages 294-294
Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease
Louis Chauvelot Delphine Gamondes Julien Berthiller Ana Nieves Sébastien Renard Judith Catella?Chatron Kais Ahmad Laurent Bertoletti Boubou Camara Emmanuel Gomez David Launay David Montani Jean?François Mornex Grégoire Prévot Olivier Sanchez Anne?Marie Schott Fabien Subtil Julie Traclet Ségolène Turquier Sabrina Zeghmar Gilbert Habib Martine Reynaud?Gaubert Marc Humbert Vincent Cottin … See fewer authors
doi : 10.1002/art.41512
Volume73, Issue2,Pages 295-304
Patients with systemic sclerosis and both pulmonary hypertension and interstitial lung disease (SSc–PH?ILD) generally carry a worse prognosis than patients with SSc and pulmonary arterial hypertension (SSc?PAH) without ILD. There is no evidence of the efficacy of PAH therapies in SSc–PH?ILD. We undertook this study to compare survival of and response to treatment in patients with SSc–PH?ILD and those with SSc?PAH.
Association of Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis With Marked Improvement in Health?Related Quality of Life
Nancy Maltez Mathieu Puyade Mianbo Wang Pauline Lansiaux Zora Marjanovic Catney Charles Russell Steele Murray Baron Ines Colmegna Marie Hudson Dominique Farge for the Canadian Scleroderma Research Group and the MATHEC?SFGMTC Network
doi : 10.1002/art.41519
Volume73, Issue2,Pages 305-314
To quantify the magnitude, domains, and duration of change in health?related quality of life (HRQoL) in patients with systemic sclerosis (SSc) who underwent autologous hematopoietic stem cell transplantation (HSCT) as compared to SSc patients with similar characteristics who did not undergo autologous HSCT.
Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex
Christopher A. Mecoli Brittany L. Adler Qingyuan Yang Laura K. Hummers Antony Rosen Livia Casciola?Rosen Ami A. Shah
doi : 10.1002/art.41493
Volume73, Issue2,Pages 315-323
The aim of this study is to describe 4 of the most common autoantibodies against components of the Th/To complex: human POP1 (hPOP1), RPP25, RPP30, and RPP40. We report their prevalence and clinical characteristics in a systemic sclerosis (SSc) population, and determine whether these specificities are associated with cancer.
Calcium Pyrophosphate Dihydrate Crystal Deposition in Gouty Tophi
Hang?Korng Ea Alan Gauffenic Quang Dinh Nguyen Nhu G. Pham Océane Olivier Vincent Frochot Dominique Bazin Nghia H. Le Caroline Marty Agnès Ostertag Martine Cohen?Solal Jean?Denis Laredo Pascal Richette Thomas Bardin
doi : 10.1002/art.41515
Volume73, Issue2,Pages 324-329
The coexistence of calcium pyrophosphate dihydrate (CPPD) and monosodium urate monohydrate crystals in gouty tophi has rarely been reported. We undertook this study to investigate CPPD crystal deposits in a series of surgically removed gouty tophi and to identify factors associated with these deposits.
Imaging?Based Uveitis Surveillance in Juvenile Idiopathic Arthritis: Feasibility, Acceptability, and Diagnostic Performance
Saira Akbarali Jugnoo S. Rahi Andrew D. Dick Kiren Parkash Katie Etherton Clive Edelsten Xiaoxuan Liu Ameenat L. Solebo
doi : 10.1002/art.41530
Volume73, Issue2,Pages 330-335
Children with juvenile idiopathic arthritis (JIA) need regular examinations for uveitis to avoid visual morbidity from the most common extraarticular manifestation of disease. This study was undertaken to investigate the feasibility, acceptability, and performance of optical coherence tomography (OCT) imaging?based diagnosis of uveitis.
Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open?Label, Randomized Study
Pierre Quartier Ekaterina Alexeeva Tamàs Constantin Vyacheslav Chasnyk Nico Wulffraat Karin Palmblad Carine Wouters Hermine I. Brunner Katherine Marzan Rayfel Schneider Gerd Horneff Alberto Martini Jordi Anton Xiaoling Wei Alan Slade Nicolino Ruperto Ken Abrams the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group
doi : 10.1002/art.41488
Volume73, Issue2,Pages 336-346
To evaluate the efficacy and safety of 2 canakinumab monotherapy tapering regimens in order to maintain complete clinical remission in children with systemic juvenile idiopathic arthritis (JIA).
Incidence, Clinical Features, and Outcomes of Late?Onset Neutropenia From Rituximab for Autoimmune Disease
Reza Zonozi Zachary S. Wallace Karen Laliberte Noah R. Huizenga Jillian M. Rosenthal Eugene P. Rhee Frank B. Cortazar John L. Niles
doi : 10.1002/art.41501
Volume73, Issue2,Pages 347-354
Late?onset neutropenia (LON) is an underrecognized complication of rituximab treatment. We undertook this study to describe its incidence, risk factors, clinical features, management, and recurrence.
High Prevalence of New?Onset or Worsening Hepatitis C Virus–Related Musculoskeletal Symptoms After Beginning Direct?Acting Antiviral Therapy: A Challenging Novel Observation
Muhammad Haroon Khurram Anis Zara Khan Naila Nawaz
doi : 10.1002/art.41496
Volume73, Issue2,Pages 355-356
Morning Stiffness and Neutrophil Circadian Disarming: Comment on the Article by Orange et al
Omer Nuri Pamuk Sarfaraz Hasni
doi : 10.1002/art.41503
Volume73, Issue2,Pages 356-357
Reply
Dana E. Orange Nathalie E. Blachere Mayu O. Frank Salina Parveen Edward F. DiCarlo Serene Mirza Tania Pannellini Mark P. Figgie Vivian P. Bykerk Caroline S. Jiang Ellen M. Gravallese Ana?Maria Orbai Sarah L. Mackie Susan M. Goodman … See fewer authors
doi : 10.1002/art.41505
Volume73, Issue2,Pages 357-358
Early?Onset Hydroxychloroquine Retinopathy and a Possible Relationship to Blood Levels: Comment on the Article by Petri et al
Naoto Yokogawa Akiko Ohno?Tanaka Masayuki Hashiguchi Mikiko Shimizu Hiroko Ozawa Shinji Ueno Kei Shinoda David J. Browning
doi : 10.1002/art.41497
Volume73, Issue2,Pages 358-359
Reply
Michelle Petri Marwa Elkhalifa Laurence S. Magder Jessica Li Daniel W. Goldman
doi : 10.1002/art.41521
Volume73, Issue2,Pages 359-359
To Switch or Not Switch Febuxostat: Comment on the Article by FitzGerald et al
Chuanhui Xu
doi : 10.1002/art.41504
Volume73, Issue2,Pages 359-360
